Nanjing, China-based Micro-Tech, which has its U.S. base in Ann Arbor, Michigan, acquired the rights for the Duraclip, Precisor and Optibite lines, which Conmed has sold on behalf of the company for more than a decade.
Micro-Tech said the agreement follows Conmed’s decision to exit the gastroenterology line, announced in December 2025. The company said it can now integrate the product lines into its own GI endoscopy portfolio.
According to the company, Duraclip enhances its hemostasis portfolio, while Precisor and Optibite extend the reach of its biopsy line. They join the company’s dual-action tissue (DAT) closure device and eyeMAX cholangioscopy system. This positions the company to serve the clinical needs of ambulatory surgery center (ASC) and hospital settings.
Micro-Tech said the transaction remains subject to customary closing conditions. Once complete, it expects to integrate the product lines into its U.S. and global commercial operations.
Commentary from Micro-Tech and Conmed officials
Scott VanderMeer, president of Micro-Tech Endoscopy Americas, said:
“This agreement reflects our continued commitment to expanding access to a broad range of GI endoscopy tools. By adding Duraclip, Precisor, and Optibite to our portfolio, we are strengthening our position in the GI market and reinforcing our role as a trusted partner to clinicians.”
Pete Shagory, VP & GM, Advanced Endoscopic Technologies at Conmed, said:
“We are pleased to transition these product lines from Conmed to Micro-Tech and believe they are well positioned to continue the strong legacy these products have established in the GI market. Micro-Tech has long served as the original manufacturer behind the Duraclip, Precisor, and Optibite devices and brings extensive experience in its design and production. We are committed to supporting a smooth transition for customers.”
